Hematologi SE

At the European Hematology Association (EHA) 2024 Congress, Hanne Norseth, MD, PhD student, Oslo Myeloma Center, Norway, presents a study that aims to evaluate vaccinating against mutated RAS in multiple myeloma. In this MEDtalk, Hanne Norseth presents the tentative data of the ongoing study. 🔗See more from the EHA24 Congress: https://lnkd.in/dPW-ansy  #EHA24 #Myelom

For patients with Factor VII deficiency, approximately 78% of the disease-associated mutations are missense mutations, with no treatment available to directly address the underlying genetic defect. In this study, Maria Eugenia Chollet presents the result of using stem cell and organoids technology together with gene editing, to correct a common F VII missense mutation and evaluate the recovery of FVII protein production and function in patient-derived cells. #EHA24 #Hematology #FVIIDeficiency

Frida Bugge Askeland, MD and investigator at Oslo Myeloma Center in Norway, presents the REMNANT Trial in this MEDtalk from her poster at the European Hematology Association (EHA) 2024 Congress . This trial will evaluate whether treating MRD relapse after first-line treatment will prolong progression-free survival and overall survival in myeloma patients. 🔗Following along as we cover the 2024 EHA Congress: https://lnkd.in/dPW-ansy  #EHA24 #Myeloma

The aim of this study was to identify novel molecular vulnerabilities in del (5q), Deletion of the long arm of chromosome 5, one of the most common chromosomal alterations in myeloid malignancies. In this MEDtalk from the European Hematology Association (EHA) 2024 Congress, Sergio Martinez Høyer, research specialist at Karolinska Institutet, Sweden, explains why RBM22 is an excellent target with a wide therapeutic window in del (5q)myeloid neoplasms. 🔗See more from our coverage from EHA24: https://lnkd.in/dPW-ansy  #EHA24 #Hematology

We all know that even if several patients have the same diagnosis, they may not respond the same way to the same therapy. During the European Hematology Association (EHA) 2024 Congress, Sigrid Skånland, Institute for Cancer Research in Oslo, presented a general lecture on the status of precision hematology. As you can hear in this MEDtalk, Sigrid Skånland explained why genomic precision medicine is not enough and why drug sensitivity screening of the patient's cells can be a step forward in future treatment. 🔗See more from the EHA Congress: https://lnkd.in/dPW-ansy  #EHA24 #Hematology

Henrik Hjorth-Hansen, Professor, Head of Department of Hematology, St Olavs Hospital HF, Trondheim, Norway, presents the ELN recommendations. The new recommendation summarizes treatment approaches for acute lymphoblastic leukemia, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and supportive care. In this MEDtalk, Henrik Hjorth-Hansen presents some of the discussion and gives his perspective. 🔗See more from the European Hematology Association (EHA) 2024: https://lnkd.in/dPW-ansy  #EHA24 #ALL

This study, presented by Rasmus Rask Kragh Jørgensen, Statistician, PhD student, Aalborg University Hospital, Denmark, provides insight into the data requirements for developing prediction models for Hodgkin lymphoma with the possibility of extension to other lymphoma types. This can potentially improve the validation of prediction models for survival among Hodgkin lymphoma patients. 🔗Stay updated on the European Hematology Association (EHA) 2024 congress; https://lnkd.in/dPW-ansy #EHA24 #Hodgkinslymphoma

Ângela Mesquita, PhD student, University of Bergen, Norway, presents in this MEDtalk from the European Hematology Association (EHA) 2024 a new model for predicting treatment efficacy for patients with Myelodysplastic syndromes. This new model may be a better predictor of treatment efficacy as it will integrate the critical role of the microenvironment. 🔗See more from the EHA 2024 congress;  https://lnkd.in/dPW-ansy  #EHA24 #Hematology

This study, presented at European Hematology Association (EHA) 2024 by Jelena Jelicic, shows that selecting patients for clinical trials based on the National Comprehensive Cancer Network IPI (NCCN-IPI) leads to more patients qualifying to participate in clinical trials. However, the study also shows that a smaller population of patients with excellent prognoses is excluded from participation. 🔗See our coverage of the EHA congress; https://lnkd.in/dPW-ansy  #EHA #Hematology

This study on long-term follow-up in relapsed mantle cell lymphoma involved a combination of lenalidomide, rituximab, and ibrutinib. Conducted in the Nordic countries, it showed a median progression-free survival of 70.4 months, even in TP53 mutated cases. Elin Forsgren, Uppsala University, presents the study in this MEDtalk at the European Hematology Association (EHA) 2024. 🔗See more from the EHA congress; https://lnkd.in/dPW-ansy  #EHA24 #Hematology